ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Comprehensive Centers Could Lose That Designation By Not Producing

May 30, 1975

In Brief: President OK’s Mammography Standard Publication, CDC State Grants Increase

January 7, 1994

Funding Opportunities

September 6, 2002

FDA Approves New Drug for Advanced Kidney Cancer

May 25, 2007

NCI Cancer Bulletin publicized board’s resignation over liability concerns.

April 16, 2004

Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.

May 4, 2001